- Home
- ORIC vs ORGO Comparison
ORIC vs ORGO Comparison
Compare ORIC & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- ORGO
- Stock Information
- Founded
- ORIC 2014
- ORGO 1985
- Country
- ORIC United States
- ORGO United States
- Employees
- ORIC N/A
- ORGO N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- ORGO Health Care
- Exchange
- ORIC Nasdaq
- ORGO Nasdaq
- Market Cap
- ORIC 362.9M
- ORGO 384.4M
- IPO Year
- ORIC 2020
- ORGO N/A
- Fundamental
- Price
- ORIC $9.35
- ORGO $3.25
- Analyst Decision
- ORIC Strong Buy
- ORGO Buy
- Analyst Count
- ORIC 8
- ORGO 2
- Target Price
- ORIC $18.83
- ORGO $5.50
- AVG Volume (30 Days)
- ORIC 2.0M
- ORGO 853.3K
- Earning Date
- ORIC 08-11-2025
- ORGO 08-07-2025
- Dividend Yield
- ORIC N/A
- ORGO N/A
- EPS Growth
- ORIC N/A
- ORGO N/A
- EPS
- ORIC N/A
- ORGO N/A
- Revenue
- ORIC N/A
- ORGO $458,760,000.00
- Revenue This Year
- ORIC N/A
- ORGO $2.62
- Revenue Next Year
- ORIC N/A
- ORGO $12.46
- P/E Ratio
- ORIC N/A
- ORGO N/A
- Revenue Growth
- ORIC N/A
- ORGO 5.35
- 52 Week Low
- ORIC $3.90
- ORGO $2.28
- 52 Week High
- ORIC $14.67
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- ORIC 62.84
- ORGO 48.02
- Support Level
- ORIC $8.85
- ORGO $3.08
- Resistance Level
- ORIC $9.54
- ORGO $3.71
- Average True Range (ATR)
- ORIC 0.74
- ORGO 0.21
- MACD
- ORIC -0.07
- ORGO 0.07
- Stochastic Oscillator
- ORIC 50.98
- ORGO 55.45
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.